Scientists and trainees from Yale Cancer Center attended the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, held May 29–June 2, to showcase groundbreaking research from Yale Cancer Center and Smilow Cancer Hospital. The largest and most influential gathering of oncology professionals in the world, the ASCO meeting fosters critical connections and collaborations that shape the future of cancer care.
Dr. Roy S. Herbst joined Dr. Karen Knudsen to discuss the state of oncology in 2026 with STAT News at ASCO hosted by journalist Angus Rohan Chen.
Dr. Roy S. Herbst joined Dr. Karen Knudsen to discuss the state of oncology in 2026 with STAT News at ASCO hosted by journalist Angus Rohan Chen.
Dr. Roy S. Herbst joined Dr. Karen Knudsen to discuss the state of oncology in 2026 with STAT News at ASCO hosted by journalist Angus Rohan Chen.
During the meeting, four trainees were honored with the Conquer Cancer Foundation Young Investigator Award including, Caroline Richburg, MD, Paul Stockhammer, MD, PhD, Rajal Sharmat, MD, PhD, and Krishna Iyer, MD, PhD. Lajos Pusztai, MD, received the Giant of Cancer Care award for his work in Cancer Prevention/Genetics, and Shira Gabizon Peretz, MD, Maryam Mooghali, MD, MSc, and Amin Nassar, MD, all received ASCO Merit Awards.
Dr. Eric Winer moderates a case-based panel exploring management of advanced/metastatic HER2+ breast cancer, highlighting how cancer progression, treatment response, therapy options, and, most importantly, patient preferences and decisions, shape treatment goals.
Dr. So Yeon Kim and Dr. Juan Manuel O’Connor lead a Rapid Oral Abstract Session in Developmental Therapeutics on Immunotherapy.
Dr. Aarti Bhatia discusses the impact of neoadjuvant and adjuvant therapy for head and neck cancer through a comprehensive review of data presented from the AREST, NIVOPOSTOP & MACE-POSTOP trials during an Oral Abstract Session.
Dr. Harriet Kluger leads an Oral Abstract Session on the immense promise of cellular therapies, BiTEs, and therapies targeting cell surface proteins, pushing for durable, long term responses, additional targets, and more applications.
During an Oral Abstract Session, Dr. David Rimm discussed new data suggesting AI can “read” standard pathology slides to infer molecular signals that usually require extra lab tests, a potentially faster and more accessible method. Still research, not yet a replacement for today’s validated companion diagnostics.
Dr. Eric Winer moderates a case-based panel exploring management of advanced/metastatic HER2+ breast cancer, highlighting how cancer progression, treatment response, therapy options, and, most importantly, patient preferences and decisions, shape treatment goals.
Dr. So Yeon Kim and Dr. Juan Manuel O’Connor lead a Rapid Oral Abstract Session in Developmental Therapeutics on Immunotherapy.
Dr. Aarti Bhatia discusses the impact of neoadjuvant and adjuvant therapy for head and neck cancer through a comprehensive review of data presented from the AREST, NIVOPOSTOP & MACE-POSTOP trials during an Oral Abstract Session.
Dr. Harriet Kluger leads an Oral Abstract Session on the immense promise of cellular therapies, BiTEs, and therapies targeting cell surface proteins, pushing for durable, long term responses, additional targets, and more applications.
During an Oral Abstract Session, Dr. David Rimm discussed new data suggesting AI can “read” standard pathology slides to infer molecular signals that usually require extra lab tests, a potentially faster and more accessible method. Still research, not yet a replacement for today’s validated companion diagnostics.
Dr. Eric Winer moderates a case-based panel exploring management of advanced/metastatic HER2+ breast cancer, highlighting how cancer progression, treatment response, therapy options, and, most importantly, patient preferences and decisions, shape treatment goals.
Dr. So Yeon Kim and Dr. Juan Manuel O’Connor lead a Rapid Oral Abstract Session in Developmental Therapeutics on Immunotherapy.
Dr. Aarti Bhatia discusses the impact of neoadjuvant and adjuvant therapy for head and neck cancer through a comprehensive review of data presented from the AREST, NIVOPOSTOP & MACE-POSTOP trials during an Oral Abstract Session.
Dr. Harriet Kluger leads an Oral Abstract Session on the immense promise of cellular therapies, BiTEs, and therapies targeting cell surface proteins, pushing for durable, long term responses, additional targets, and more applications.
During an Oral Abstract Session, Dr. David Rimm discussed new data suggesting AI can “read” standard pathology slides to infer molecular signals that usually require extra lab tests, a potentially faster and more accessible method. Still research, not yet a replacement for today’s validated companion diagnostics.
To relax and reconnect, Yale Cancer Center hosted a reception on Sunday evening for current and former oncology faculty and trainees. The event offered a welcome break from the fast pace of the ASCO meeting.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
Yale Cancer Center hosted a wonderful evening at ASCO 2026 to connect with colleagues and catch up with friends at our annual reception.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
We had a wonderful evening at the Yale reception during American Society of Clinical Oncology (ASCO) annual meeting reconnecting with colleagues, alumni, collaborators, and friends from across the oncology community.
The 2026 ASCO Annual Meeting featured over 200 sessions complementing Dr. Eric Small’s Presidential theme, The Science and Practice of Translation: Improving Cancer Outcomes Worldwide. Yale Cancer Center contributed over 60 oral, educational, and poster presentations, highlighting significant advances in cancer treatment and care driven by clinical trials and translational research from Smilow Cancer Hospital.
Dr. Damian McGlothlin and Dr. Raghav Sundar present a study of gastric cancer: Tumors with high CDH17 tended to have a more “immune-cold” environment. This may help explain why some tumors are harder to treat and points to CDH17 as a potential target.
Dr. Olivia Lynch presents a study of US patients with breast cancer <65: as care improved, income gaps persisted, especially for immediate reconstruction after mastectomy and Oncotype DX testing. Some treatment gaps are shrinking, but disparities remain.
Dr. Cary Gross presents data from a SEER study of 435k Medicare patients with cancer showing that nonwhite and foreign-born oncologists more often care for underserved patients (racial/ethnic minority and low-income). Noting that policies that reduce physician diversity could worsen access to cancer care.
New research in advanced colorectal cancer from Dr. Xuanyi Li suggests a liquid biopsy can detect MTAP gene loss. MTAP loss was reliably seen when tumor fraction ≥5% and was similar to tissue testing at that level, beneficial when biopsy tissue is limited.
Kerry Conlin shares US survey data (2005-2024) showing flu vaccination among cancer survivors rose from 45.5% to 63.3%—but over 1 in 3 were still unvaccinated in 2024. Rates were especially low for younger survivors, the uninsured, those without a usual place for care, and Hispanic survivors, highlighting persistent gaps.
Dr. Damian McGlothlin and Dr. Raghav Sundar present a study of gastric cancer: Tumors with high CDH17 tended to have a more “immune-cold” environment. This may help explain why some tumors are harder to treat and points to CDH17 as a potential target.
Dr. Olivia Lynch presents a study of US patients with breast cancer <65: as care improved, income gaps persisted, especially for immediate reconstruction after mastectomy and Oncotype DX testing. Some treatment gaps are shrinking, but disparities remain.
Dr. Cary Gross presents data from a SEER study of 435k Medicare patients with cancer showing that nonwhite and foreign-born oncologists more often care for underserved patients (racial/ethnic minority and low-income). Noting that policies that reduce physician diversity could worsen access to cancer care.
New research in advanced colorectal cancer from Dr. Xuanyi Li suggests a liquid biopsy can detect MTAP gene loss. MTAP loss was reliably seen when tumor fraction ≥5% and was similar to tissue testing at that level, beneficial when biopsy tissue is limited.
Kerry Conlin shares US survey data (2005-2024) showing flu vaccination among cancer survivors rose from 45.5% to 63.3%—but over 1 in 3 were still unvaccinated in 2024. Rates were especially low for younger survivors, the uninsured, those without a usual place for care, and Hispanic survivors, highlighting persistent gaps.
Dr. Damian McGlothlin and Dr. Raghav Sundar present a study of gastric cancer: Tumors with high CDH17 tended to have a more “immune-cold” environment. This may help explain why some tumors are harder to treat and points to CDH17 as a potential target.
Dr. Olivia Lynch presents a study of US patients with breast cancer <65: as care improved, income gaps persisted, especially for immediate reconstruction after mastectomy and Oncotype DX testing. Some treatment gaps are shrinking, but disparities remain.
Dr. Cary Gross presents data from a SEER study of 435k Medicare patients with cancer showing that nonwhite and foreign-born oncologists more often care for underserved patients (racial/ethnic minority and low-income). Noting that policies that reduce physician diversity could worsen access to cancer care.
New research in advanced colorectal cancer from Dr. Xuanyi Li suggests a liquid biopsy can detect MTAP gene loss. MTAP loss was reliably seen when tumor fraction ≥5% and was similar to tissue testing at that level, beneficial when biopsy tissue is limited.
Kerry Conlin shares US survey data (2005-2024) showing flu vaccination among cancer survivors rose from 45.5% to 63.3%—but over 1 in 3 were still unvaccinated in 2024. Rates were especially low for younger survivors, the uninsured, those without a usual place for care, and Hispanic survivors, highlighting persistent gaps.
Dr. Raghave Sundar shares how testing for CLDN18.2 in advanced stomach/GE junction cancer is increasing, but still lags. About 1 in 3 patients get key biomarker tests months apart, which can delay the best treatment choice—supporting doing all tests up front.
In patients across 18 cancers with POLE/POLD1 variants, Dr. Amin Nassar and colleagues found that combining mutational signatures with AI protein modeling helps identify which variants disrupt DNA proofreading—and better predicts benefit from immune checkpoint therapy.
Drs. David Schoenfeld and Harriet Kluger share data from ph 1 trial of AB248 alone/with pembro in patients with advanced/metastatic melanoma. In pretreated patients, confirmed partial responses were seen: 18% w high-dose AB248 alone (cutaneous), 12% w combo (cutaneous), and 27% w combo (mucosal), supporting more study.
Dr. David Braun and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing.
Dr. Barbara Burtness shares updated results from KEYNOTE‑412 in unresected locally advanced head & neck squamous cell carcinoma. In patients with high PD‑L1 expression, adding pembro to CRT improved outcomes vs CRT alone: 60‑month event‑free survival 62.4% vs 50.3%, with overall survival also trending better.
Dr. Raghave Sundar shares how testing for CLDN18.2 in advanced stomach/GE junction cancer is increasing, but still lags. About 1 in 3 patients get key biomarker tests months apart, which can delay the best treatment choice—supporting doing all tests up front.
In patients across 18 cancers with POLE/POLD1 variants, Dr. Amin Nassar and colleagues found that combining mutational signatures with AI protein modeling helps identify which variants disrupt DNA proofreading—and better predicts benefit from immune checkpoint therapy.
Drs. David Schoenfeld and Harriet Kluger share data from ph 1 trial of AB248 alone/with pembro in patients with advanced/metastatic melanoma. In pretreated patients, confirmed partial responses were seen: 18% w high-dose AB248 alone (cutaneous), 12% w combo (cutaneous), and 27% w combo (mucosal), supporting more study.
Dr. David Braun and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing.
Dr. Barbara Burtness shares updated results from KEYNOTE‑412 in unresected locally advanced head & neck squamous cell carcinoma. In patients with high PD‑L1 expression, adding pembro to CRT improved outcomes vs CRT alone: 60‑month event‑free survival 62.4% vs 50.3%, with overall survival also trending better.
Dr. Raghave Sundar shares how testing for CLDN18.2 in advanced stomach/GE junction cancer is increasing, but still lags. About 1 in 3 patients get key biomarker tests months apart, which can delay the best treatment choice—supporting doing all tests up front.
In patients across 18 cancers with POLE/POLD1 variants, Dr. Amin Nassar and colleagues found that combining mutational signatures with AI protein modeling helps identify which variants disrupt DNA proofreading—and better predicts benefit from immune checkpoint therapy.
Drs. David Schoenfeld and Harriet Kluger share data from ph 1 trial of AB248 alone/with pembro in patients with advanced/metastatic melanoma. In pretreated patients, confirmed partial responses were seen: 18% w high-dose AB248 alone (cutaneous), 12% w combo (cutaneous), and 27% w combo (mucosal), supporting more study.
Dr. David Braun and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing.
Dr. Barbara Burtness shares updated results from KEYNOTE‑412 in unresected locally advanced head & neck squamous cell carcinoma. In patients with high PD‑L1 expression, adding pembro to CRT improved outcomes vs CRT alone: 60‑month event‑free survival 62.4% vs 50.3%, with overall survival also trending better.
Dr. Harriet Kluger presents the ph 1 trial (NCT07027488) of AB821 for patients with advanced melanoma and other immune-responsive solid tumors. Accrual is ongoing.
Presented by Dr. Curtis Pickering and Parisa Bedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer.
TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. Among patients receiving immunotherapy, DDR mutations were associated with poorer survival, while high TMB was linked to improved survival.
Presented by Dr. Curtis Pickering and Parisa Bedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer.
TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. Among patients receiving immunotherapy, DDR mutations were associated with poorer survival, while high TMB was linked to improved survival.
Yale research led by Drs. Shira Gabizon Peretz and Harriet Kluger found an inherited NLRC5 variant (Pro191Leu) was more common in patients who developed ICI–induced hepatitis (30% vs 12.8% in the general pop). Carriers also had more endocrine immune side effects, suggesting genetics may help predict and monitor immunotherapy toxicity
Dr. Roy Herbst highlights MarsLight-11, a ph 3 trial in NSCLC that has progressed after both chemo & immuno. It compares docetaxel vs IBI363, a new immune drug designed to block PD‑1 while also giving a targeted IL‑2 ‘boost.’
Dr. Harriet Kluger presents the ph 1 trial (NCT07027488) of AB821 for patients with advanced melanoma and other immune-responsive solid tumors. Accrual is ongoing.
Presented by Dr. Curtis Pickering and Parisa Bedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer.
TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. Among patients receiving immunotherapy, DDR mutations were associated with poorer survival, while high TMB was linked to improved survival.
Presented by Dr. Curtis Pickering and Parisa Bedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer.
TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. Among patients receiving immunotherapy, DDR mutations were associated with poorer survival, while high TMB was linked to improved survival.
Yale research led by Drs. Shira Gabizon Peretz and Harriet Kluger found an inherited NLRC5 variant (Pro191Leu) was more common in patients who developed ICI–induced hepatitis (30% vs 12.8% in the general pop). Carriers also had more endocrine immune side effects, suggesting genetics may help predict and monitor immunotherapy toxicity
Dr. Roy Herbst highlights MarsLight-11, a ph 3 trial in NSCLC that has progressed after both chemo & immuno. It compares docetaxel vs IBI363, a new immune drug designed to block PD‑1 while also giving a targeted IL‑2 ‘boost.’
Dr. Harriet Kluger presents the ph 1 trial (NCT07027488) of AB821 for patients with advanced melanoma and other immune-responsive solid tumors. Accrual is ongoing.
Presented by Dr. Curtis Pickering and Parisa Bedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer.
TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. Among patients receiving immunotherapy, DDR mutations were associated with poorer survival, while high TMB was linked to improved survival.
Presented by Dr. Curtis Pickering and Parisa Bedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer.
TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. Among patients receiving immunotherapy, DDR mutations were associated with poorer survival, while high TMB was linked to improved survival.
Yale research led by Drs. Shira Gabizon Peretz and Harriet Kluger found an inherited NLRC5 variant (Pro191Leu) was more common in patients who developed ICI–induced hepatitis (30% vs 12.8% in the general pop). Carriers also had more endocrine immune side effects, suggesting genetics may help predict and monitor immunotherapy toxicity
Dr. Roy Herbst highlights MarsLight-11, a ph 3 trial in NSCLC that has progressed after both chemo & immuno. It compares docetaxel vs IBI363, a new immune drug designed to block PD‑1 while also giving a targeted IL‑2 ‘boost.’
Dr. Dan Petrylak shared Duravelo-2 interim results: BT8009, a targeted therapy for advanced bladder cancer, helped shrink tumors in about 3 in 10 patients whose cancer had already been treated. The 6 mg/m² schedule showed the best balance of benefit and side effects.
Dr. Soki Kashima and Dr. David Braun share why some kidney cancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance.
Dr. Sarah Goldberg presents early COPERNICUS safety results suggesting that subcutaneous amivantamab every 4 weeks + daily lazertinib for newly diagnosed EGFR-mutant advanced lung cancer may be easier to tolerate with proactive supportive care. Longer follow-up is ongoing.
Gabriela Esnaola shares a study of metastatic NSCLC showing that patterns of where cancer spreads predict survival & treatment response better than looking at single organs alone. This “metastasis profile” approach could improve therapy decisions.
Dr. Dan Petrylak shared Duravelo-2 interim results: BT8009, a targeted therapy for advanced bladder cancer, helped shrink tumors in about 3 in 10 patients whose cancer had already been treated. The 6 mg/m² schedule showed the best balance of benefit and side effects.
Dr. Soki Kashima and Dr. David Braun share why some kidney cancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance.
Dr. Sarah Goldberg presents early COPERNICUS safety results suggesting that subcutaneous amivantamab every 4 weeks + daily lazertinib for newly diagnosed EGFR-mutant advanced lung cancer may be easier to tolerate with proactive supportive care. Longer follow-up is ongoing.
Gabriela Esnaola shares a study of metastatic NSCLC showing that patterns of where cancer spreads predict survival & treatment response better than looking at single organs alone. This “metastasis profile” approach could improve therapy decisions.
Dr. Dan Petrylak shared Duravelo-2 interim results: BT8009, a targeted therapy for advanced bladder cancer, helped shrink tumors in about 3 in 10 patients whose cancer had already been treated. The 6 mg/m² schedule showed the best balance of benefit and side effects.
Dr. Soki Kashima and Dr. David Braun share why some kidney cancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance.
Dr. Sarah Goldberg presents early COPERNICUS safety results suggesting that subcutaneous amivantamab every 4 weeks + daily lazertinib for newly diagnosed EGFR-mutant advanced lung cancer may be easier to tolerate with proactive supportive care. Longer follow-up is ongoing.
Gabriela Esnaola shares a study of metastatic NSCLC showing that patterns of where cancer spreads predict survival & treatment response better than looking at single organs alone. This “metastasis profile” approach could improve therapy decisions.
Drs. Alessandro Santin and Stefania Bellone share promising data on a phase II study (NCT06028932) of sacituzumab govitecan for ovarian cancer: 35% had tumor shrinkage and 40% had stable disease in 20 heavily pretreated patients.
Dr. Maryam Mooghali shares her poster: commercial pricing for biomarker tests varies substantially across US hospitals and insurers. Variation is greater between hospitals than within for the same test—with implications for spending, patient out-of-pocket costs & equitable access to guideline-recommended cancer care.
Dr. Tamar Kaminski shared that ~1 in 10 women ≥65 with advanced breast cancer had an HRD genomic signature, potentially identifying patients for PARP inhibitor therapy. HRD+ tumors were enriched for BRCA1/2 and other DNA-repair alterations, supporting future PARP + immunotherapy studies.
Dr. Adriana Kahn reported that primary breast cancer tumors and skin metastases share many of the same DNA changes, though skin metastases more often had alterations linked to estrogen signaling and tumor spread. Targetable mutations were common in both, highlighting the value of genomic testing.
Drs. Alessandro Santin and Stefania Bellone share promising data on a phase II study (NCT06028932) of sacituzumab govitecan for ovarian cancer: 35% had tumor shrinkage and 40% had stable disease in 20 heavily pretreated patients.
Dr. Maryam Mooghali shares her poster: commercial pricing for biomarker tests varies substantially across US hospitals and insurers. Variation is greater between hospitals than within for the same test—with implications for spending, patient out-of-pocket costs & equitable access to guideline-recommended cancer care.
Dr. Tamar Kaminski shared that ~1 in 10 women ≥65 with advanced breast cancer had an HRD genomic signature, potentially identifying patients for PARP inhibitor therapy. HRD+ tumors were enriched for BRCA1/2 and other DNA-repair alterations, supporting future PARP + immunotherapy studies.
Dr. Adriana Kahn reported that primary breast cancer tumors and skin metastases share many of the same DNA changes, though skin metastases more often had alterations linked to estrogen signaling and tumor spread. Targetable mutations were common in both, highlighting the value of genomic testing.
Drs. Alessandro Santin and Stefania Bellone share promising data on a phase II study (NCT06028932) of sacituzumab govitecan for ovarian cancer: 35% had tumor shrinkage and 40% had stable disease in 20 heavily pretreated patients.
Dr. Maryam Mooghali shares her poster: commercial pricing for biomarker tests varies substantially across US hospitals and insurers. Variation is greater between hospitals than within for the same test—with implications for spending, patient out-of-pocket costs & equitable access to guideline-recommended cancer care.
Dr. Tamar Kaminski shared that ~1 in 10 women ≥65 with advanced breast cancer had an HRD genomic signature, potentially identifying patients for PARP inhibitor therapy. HRD+ tumors were enriched for BRCA1/2 and other DNA-repair alterations, supporting future PARP + immunotherapy studies.
Dr. Adriana Kahn reported that primary breast cancer tumors and skin metastases share many of the same DNA changes, though skin metastases more often had alterations linked to estrogen signaling and tumor spread. Targetable mutations were common in both, highlighting the value of genomic testing.
Dr. Raghav Sundar presents an Education Session: Breaking the Immune Sanctuary: Targeting Metastatic Niches.” Metastasis may not be random—immune and cellular niches matter. These metastatic “sanctuary” sites can limit immunotherapy responses, underscoring the need for better treatment strategies. Understanding these niches may be the next frontier in cancer therapy.
Dr. Barbara Burtness presented impressive results from OrigAMI-4 (ph 1b/2) in HPV-unrelated recurrent/met head & neck cancer during an Oral Abstract Session: amivantamab had an ORR of 42% in patients and 15% had complete response. Most patients (79%) had some tumor shrinkage. Responses happened fast (~6.6 weeks) and were durable.
Dr. Raghav Sundar presents an Education Session: Breaking the Immune Sanctuary: Targeting Metastatic Niches.” Metastasis may not be random—immune and cellular niches matter. These metastatic “sanctuary” sites can limit immunotherapy responses, underscoring the need for better treatment strategies. Understanding these niches may be the next frontier in cancer therapy.
Dr. Barbara Burtness presented impressive results from OrigAMI-4 (ph 1b/2) in HPV-unrelated recurrent/met head & neck cancer during an Oral Abstract Session: amivantamab had an ORR of 42% in patients and 15% had complete response. Most patients (79%) had some tumor shrinkage. Responses happened fast (~6.6 weeks) and were durable.
Dr. Raghav Sundar presents an Education Session: Breaking the Immune Sanctuary: Targeting Metastatic Niches.” Metastasis may not be random—immune and cellular niches matter. These metastatic “sanctuary” sites can limit immunotherapy responses, underscoring the need for better treatment strategies. Understanding these niches may be the next frontier in cancer therapy.
Dr. Barbara Burtness presented impressive results from OrigAMI-4 (ph 1b/2) in HPV-unrelated recurrent/met head & neck cancer during an Oral Abstract Session: amivantamab had an ORR of 42% in patients and 15% had complete response. Most patients (79%) had some tumor shrinkage. Responses happened fast (~6.6 weeks) and were durable.
Copy Link